Gapping up
In reaction to earnings/guidance:
- LI +29%, FTCH +13.2%, DKNG +9.7%, VIPS +7.8%, CSCO +7.2% (also new CFO), SPB +7.1%, DDS +6.5%, DIS +4% (beats handily, Disney+ paid subs totaled 73.7 mln), ADSK +3.2% (sees Q3 results above guidance; also CFO departs) DLB +3.1%, AMAT +2.9%, JAMF +2.8%, AQN +1.7%
Other news:
- UROV +92.9% (Sumitovant Biopharma to acquire rest of UROV it does not already own)
- IPHA +13.1% (receives Prime Designation from the EMA for Lacutamab)
- FPRX +4.8% (prices offering of 7.2 mln shares of common stock at $21.00 per share)
- BCRX +4.5% (presents data showing sustained attack rate reductions, improved patient satisfaction and quality of life for HAE patients taking Berotralstat in APeX-2 Trial ) KPTI +4% (announces publication of XPOVIO Phase 3 BOSTON study)
- NKTX +3.1% (treats first patient in first-in-human Phase 1 clinical trial of NKX101)
- CAMT +3.1% (receives over $20 million in orders for inspection & metrology systems from several manufacturers; orders are expected to be delivered during the first half of 2021)
- AGIO +2.2% (receives FDA orphan drug designation for mitapivat)
- BBIO +2% (BridgeBio Pharma and affiliate navire pharma announce dosing of first patient in phase 1 clinical trial of SHP2 inhibitor BBP-398 for tumors driven by RAS and receptor tyrosine kinase mutations)
- TAL +1.6% (investment firm to purchase $1.5 bln of newly issued Class A shares)
- ENB +1.5% (Line 3 replacement project receives MPCA approvals)
- ORTX +1.5% (discloses new research program in ALS; to unveil details on new HSC gene therapy research)
- CAR +1.3% (S&P ratings affirmed on improved liquidity; outlook negative)
- SYY +1.1% (eliminates minimum delivery size requirements)
Analyst comments:
- UTZ +3.3% (upgraded to Overweight from Neutral at Piper Sandler)
- DLR +2% (upgraded to Buy from Neutral at Citigroup)
- TDOC +1.6% (upgraded to Outperform from Neutral at Robert W. Baird)